SARS-CoV-2 RNA polymerase inhibitor
Molnupiravir
Brand names: Lagevrio
Adult dose
Dose: 800mg PO BD for 5 days, started ≤5 days from symptom onset
Route: PO
Frequency: BD x 5 days
Clinical pearls
- Mild-moderate COVID-19 in non-hospitalised adults at risk of progression
- Consider after Paxlovid (if not contraindicated) per current UK COVID-19 therapeutics guidance
Contraindications
- Pregnancy (effective contraception during and 4 days after course)
- Breastfeeding
- Children <18
Side effects
- Diarrhoea
- Nausea
- Dizziness
- Headache
Monitoring
- Symptom resolution
Reference: BNF; UK COVID-19 therapeutic alerts; SmPC; https://bnf.nice.org.uk/drugs/molnupiravir/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023